Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients.

[1]  H. Schuller.  Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? , 2009, Nature Reviews Cancer.

[2]  Maarit Tiirikainen,et al.  Smokers with the CHRNA lung cancer-associated variants are exposed to higher levels of nicotine equivalents and a carcinogenic tobacco-specific nitrosamine. , 2008, Cancer research.

[3]  H. Sekhon,et al.  Activated cholinergic signaling provides a target in squamous cell lung carcinoma. , 2008, Cancer research.

[4]  G. Mills,et al.  Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1 , 2008, Nature Genetics.

[5]  H. Wit.  Faculty Opinions recommendation of Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. , 2008 .

[6]  Paolo Vineis,et al.  A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25 , 2008, Nature.

[7]  Daniel F. Gudbjartsson,et al.  A variant associated with nicotine dependence, lung cancer and peripheral arterial disease , 2008, Nature.

[8]  Gaetano Rocco,et al.  Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung , 2008, Cell cycle.

[9]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[10]  P. Muglia,et al.  α-5/α-3 nicotinic receptor subunit alleles increase risk for heavy smoking , 2008, Molecular Psychiatry.

[11]  R. Rosell,et al.  Platinum resistance related to a functional NER pathway. , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  Spyro Mousses,et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.

[13]  D. Gandara,et al.  Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Luc Girard,et al.  Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers. , 2007, Cancer research.

[15]  R. Rosell,et al.  Excision cross-complementing group 1 (ERCC1) single nucleotide polymorphisms (SNPs) and survival in cisplatin (cis)/docetaxel (doc)-treated stage IV non-small cell lung cancer (NSCLC) patients (p): A Spanish Lung Cancer Group study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Chellappan,et al.  Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Xingming Deng,et al.  Nicotine Inactivation of the Proapoptotic Function of Bax through Phosphorylation* , 2005, Journal of Biological Chemistry.

[18]  Xingming Deng,et al.  Tobacco-specific Nitrosamine 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone Promotes Functional Cooperation of Bcl2 and c-Myc through Phosphorylation in Regulating Cell Survival and Proliferation* , 2004, Journal of Biological Chemistry.

[19]  D. Neuberg,et al.  Excision Repair Cross-Complementation Group 1 Polymorphism Predicts Overall Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy , 2004, Clinical Cancer Research.

[20]  Fengqin Gao,et al.  Nicotine Induces Multi-site Phosphorylation of Bad in Association with Suppression of Apoptosis* , 2004, Journal of Biological Chemistry.

[21]  Guangdou Zhou,et al.  Regulation of acetylcholine receptor clustering by the tumor suppressor APC , 2003, Nature Neuroscience.

[22]  Fengqin Gao,et al.  A Functional Role for Nicotine in Bcl2 Phosphorylation and Suppression of Apoptosis* , 2003, The Journal of Biological Chemistry.

[23]  C. Heeschen,et al.  A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. , 2002, The Journal of clinical investigation.

[24]  L. Mei,et al.  Regulation of AChR Clustering by Dishevelled Interacting with MuSK and PAK1 , 2002, Neuron.

[25]  M. Spitz,et al.  An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. , 2002, Journal of the National Cancer Institute.

[26]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[27]  P. Dennis,et al.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. , 2001, Cancer research.

[28]  R. Maneckjee,et al.  Signalling pathways involved in nicotine regulation of apoptosis of human lung cancer cells. , 1998, Carcinogenesis.

[29]  M Paesmans,et al.  Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Crowley,et al.  Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Minna,et al.  Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[32]  H. Schuller.  Cell type specific, receptor-mediated modulation of growth kinetics in human lung cancer cell lines by nicotine and tobacco-related nitrosamines. , 1989, Biochemical pharmacology.

[33]  S. Groshen,et al.  Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Yokota,et al.  Contribution of nicotine acetylcholine receptor polymorphisms to lung cancer risk in a smoking-independent manner in the Japanese. , 2009, Carcinogenesis.

[35]  S. Hecht,et al.  Progress and challenges in selected areas of tobacco carcinogenesis. , 2008, Chemical research in toxicology.

[36]  Scott F. Saccone,et al.  Novel genes identified in a high-density genome wide association study for nicotine dependence. , 2007, Human molecular genetics.

[37]  J. Schiller,et al.  Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  C. Harris,et al.  Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. , 2003, The Journal of clinical investigation.

[39]  J. Minna.  Nicotine exposure and bronchial epithelial cell nicotinic acetylcholine receptor expression in the pathogenesis of lung cancer. , 2003, The Journal of clinical investigation.

[40]  P. Tsao,et al.  Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis , 2001, Nature Medicine.

[41]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.